CD29 (Integrin beta 1) Monoclonal Antibody (TS2/16), Super Bright™ 436, eBioscience™, Invitrogen™

Beschreibung

Description: The TS2/16 monoclonal antibody reacts with human CD29, also known as integrin beta 1, an approximately 130 kDa single-pass transmembrane glycoprotein. CD29 complexes with one of nine integrin alpha subunits to form the very late antigen (VLA) subfamily of adhesion molecules. Integrin heterodimers containing CD29 are involved in cell-cell and cell-matrix adhesion. CD29 is expressed broadly on lymphocytes and monocytes, with lower levels of expression on granulocytes. The TS2/16 antibody has been found to possess activating activity for beta 1 integrins. Applications Reported: This TS2/16 antibody has been reported for use in flow cytometric analysis. Applications Tested: This TS2/16 antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells. This may be used at 5 μL (0.125 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome. When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Staining Buffer (Product No.

SB-4401) to minimize any non- specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information. Excitation: 405 nm; Emission: 436 nm; Laser: Violet Laser Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company. CD29 (beta1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CD49a-f) determining the binding properties of beta1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most beta1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of beta1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a beta1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta.